The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Complementing the Cancer-Immunity Cycle
Open accessAbstract
T-cell responses has set a new direction for cancer immunotherapy. Neutralizing antibodies targeting immune checkpoint programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have been particularly successful for tumor types with limited therapeutic options such as melanoma and lung cancer. However, reactivation of T cells is only one step toward tumor elimination, and a substantial fraction of patients fails to respond to these therapies. In this context, combination therapies targeting more than one of the steps of the cancer-immune cycle may provide significant benefits. To find the best combinations, it is of upmost importance to understand the interplay between cancer cells and all the components of the immune response. This review focuses on the elements of the complement system that come into play in the cancer-immunity cycle. The complement system, an essential part of innate immunity, has emerged as a major regulator of cancer immunity. Complement effectors such as C1q, anaphylatoxins C3a and C5a, and their receptors C3aR and C5aR1, have been associated with tolerogenic cell death and inhibition of antitumor T-cell responses through the recruitment and/or activation of immunosuppressive cell subpopulations such as myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), or M2 tumor-associated macrophages (TAMs). Evidence is provided to support the idea that complement blocks many of the effector routes associated with the cancer-immunity cycle, providing the rationale for new therapeutic combinations aimed to enhance the antitumor efficacy of anti-PD-1/PD-L1 checkpoint inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“An effective cancer immunotherapy should be designed based on the specific resistance mechanisms underlining the rate-limiting steps in each particular patient (14, 15).”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654 · cited 2×
“These molecules modulate a diverse set of processes (23), including the initiation and regulation of effector Tcell responses (28).”
BackgroundSelf-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“Modulation of the Initiation of T-Cell Immunity by the Complement System The cancer-immunity cycle is initiated by tumor-specific neoantigens generated by somatic mutations (51).”
BackgroundHomozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Strainic, M. G., Liu, J., Huang, D., An, F., Lalli, P. N., Muqim, N., Shapiro, V. S., Dubyak, G. R., Heeger, P. S., & Medof, M. E. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.001 · Cited by 580
Production of complement components by cells of the immune system
Lubbers, R., van Essen, M. F., van Kooten, C., & Trouw, L. A. (2017) · Clinical and Experimental Immunology · doi:10.1111/cei.12952 · Cited by 480
Lalli, P. N., Strainic, M. G., Yang, M., Lin, F., Medof, M. E., & Heeger, P. S. (2008) · Blood · doi:10.1182/blood-2008-04-151068 · Cited by 271
Kwan, W.-H., van der Touw, W., Paz-Artal, E., Li, M. O., & Heeger, P. S. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121525 · Cited by 215 · cited 1×
“It has also been suggested that Tregs express C3aR and C5aR1, and that signaling through these receptors inhibits Treg function (84, 85).”
BackgroundC1q restrains autoimmunity and viral infection by regulating CD8 + T cell metabolism
Ling, G. S., Crawford, G., Buang, N., Bartok, I., Tian, K., Thielens, N. M., Bally, I., Harker, J. A., Ashton-Rickardt, P. G., Rutschmann, S., et al. (2018) · Science · doi:10.1126/science.aao4555 · Cited by 199 · cited 1×
“In fact, genetic deficiencies in C1q, as well as other elements of the classical complement pathway, can compromise the induction of self-tolerance and result in systemic autoimmune diseases (57, 58).”
BackgroundFunctional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a
Li, K., Fazekasova, H., Wang, N., Peng, Q., Sacks, S. H., Lombardi, G., & Zhou, W. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.07.033 · Cited by 108
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer
Su, Y., Liu, Y., Behrens, C. R., Bidlingmaier, S., Lee, N.-K., Aggarwal, R., Sherbenou, D. W., Burlingame, A. L., Hann, B. C., Simko, J. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121497 · Cited by 82
Cited by
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Self-citationTeijeira, Á., Garasa, S., Gato, M., Alfaro, C., Migueliz, I., Cirella, A., de Andrea, C., Ochoa, M. C., Otano, I., Etxeberria, I., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.001 · Cited by 788
Context-dependent roles of complement in cancer
Roumenina, L. T., Daugan, M. V., Petitprez, F., Sautès-Fridman, C., & Fridman, W. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0210-0 · Cited by 389
A guide to complement biology, pathology and therapeutic opportunity
Mastellos, D. C., Hajishengallis, G., & Lambris, J. D. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00926-1 · Cited by 320
Self-citationYi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
Metadata
- Authors
- Pio, R., Ajona, D., Ortiz-Espinosa, S., Mantovani, A., & Lambris, J. D.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-04-12
- Volume
- 10
- Pages
- 774-774
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2938697269
- Cited by
- 211
- References
- 17
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.